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The thermoreceptive transient receptor potential an-
kyrin 1 (TRPA1)  is important in the transmission of 
itch, and its agonist trans-cinnamaldehyde has occasio-
nally been reported to be a pruritogen in humans. Ho-
wever, no studies have accurately quantified the capabi-
lities of trans-cinnamaldehyde to induce itch and related 
dys esthetic sensations. The present study examined al-
terations in somatosensory and vasomotor parameters 
in response to topical trans-cinnamaldehyde 5% and ve-
hicle (ethanol) in 24 healthy subjects. During the study 
the following parameters were recorded: itch area and 
intensity, hyperknesis, alloknesis, neurogenic flare, skin 
blood flow and temperature. Trans-cinnamaldehyde 
evoked moderate itch sensation, flare, hyperknesis and 
alloknesis (p < 0.001). Blood flow and skin temperature 
were elevated in the area of trans-cinnamaldehyde app-
lication (p < 0.001). Significant positive correlations were 
found between blood flow and skin temperature, itch 
area and blood flow, and itch area and skin tempera-
ture. Topical trans-cinnamaldehyde proved feasible as 
a human itch model with applicability in studying itch 
mechanisms or anti-pruritic drug profiling. Key words: 
trans-cinnamaldehyde; TRPA1; itch; hyperknesis; allok-
nesis; experimental model.
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Itch (pruritus) is an unpleasant sensation that evokes an 
urge to scratch (1). Chronic itch is a major problem that 
significantly disturbs patients’ quality of life and poses 
an economic burden to societies. Treatment of chronic 
itch is a significant challenge (2). Itch is an extremely 
common symptom in many dermatological diseases (e.g. 
atopic dermatitis and urticaria), but it also occurs in a 
number of systemic disorders (e.g. chronic renal failure 
and cholestasis) (3). 
Pruritus and pain are distinct sensations that share se-
veral common mediators and receptors (4, 5). Histamine 
is one of the most studied mediators of itch. Antihistami-
nes have been used for decades for alleviating itch (6). 
However, chronic itch is often resistant to treatment with 
antihistamines. Studies have identified novel mediators 
and signalling pathways (histamine-independent) invol-
ved in the pathogenesis of itch (7–10), and novel anti-
pruritics are being developed to target these components 
(11, 12). The thermoreceptive transient receptor potential 
ankyrin 1 (TRPA1) is one of the novel proposed targets 
for itch, while it has also been described as a potential 
receptor in pain signalling (13, 14). Animal models 
of pharmacological or genetic modulation of TRPA1 
demonstrated that TRPA1 is essential for both acute 
histamine-independent itch (15) and chronic itch (16). 
Moreover, application of a TRPA1-specific antagonist, 
HC-030031, reverses experimentally-evoked itch in mice 
(17, 18). These observations support the dual contribution 
of TRPA1 in both itch and pain processing (18). 
The aim of the present study is to assess the itch-
inducing properties of TRPA1 activity by application of 
trans-cinnamaldehyde to healthy human skin, recording 
itch, itch-related psychophysical responses and vaso-
motor alterations.
TRPA1 is activated by several substances, including 
allyl isothiocyanate, gingerol, eugenol, and cinnamal-
dehyde (19). This ion-channel is expressed not only 
on sensory neurones, but also on keratinocytes (20). 
Human studies applying trans-cinnamaldehyde have so 
far investigated other roles of TRPA1, such as thermal 
and mechanical hyperalgesia, pain and neurogenic in-
flammation, but have not assessed itch beyond simply 
observing that subjects frequently report itch upon topi-
cal application (21, 22). The effect of cinnamaldehyde is 
concentration-dependent and the substance may cause a 
burning sensation, skin irritation, or heat hyperalgesia, 
especially at higher concentrations, in both rats (23) and 
humans (21). The multifaceted response to cinnamal-
dehyde might also be due to concentration-dependent 
effects on other TRP channels, e.g. TRPV3 and TRPM8, 
as described by Macpherson et al. (24). 
Namer et al. (21) used 10% cinnamaldehyde and 
L-menthol to investigate the activation of TRPA1 and 
TRPM8 in humans, and coincidentally found that cin-
namaldehyde also evoked a sensation of itch. Similarly, 
Olsen et al. (22) described that 5 out of 10 subjects 
reported a sensation of itch when cinnamaldehyde 
10% was applied on the skin. Hence, the present study 
investigated whether topical trans-cinnamaldehyde 
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could be established as a human experimental surrogate 
model of itch. We proposed that topical application of 
trans-cinnamaldehyde would induce itch and related 
dysesthetic sensations, such as alloknesis and/or hy-
perknesis, detectable through a battery of quantitative 
sensory tests (QST). Since sex differences in relation 
to pruritus are marginally studied (25, 26), both males 
and females were included in the present study to in-
vestigate potential differences based on sex in response 
to trans-cinnamaldehyde. 
MATERIALS AND METHODS (See Appendix S11)
RESULTS
No adverse event or wheal response was detected or 
reported in any participant. No significant age diffe-
rence was found between included males and females 
(Mann-Whitney rank sum test, p = 0.239). Since sex-
related differences were only found in skin temperature 
at baseline, all results and graphs with the exception 
of the temporal itch intensity profile, represent pooled 
data from the 21 included subjects.
Itch intensity and perceived itch area following trans-
cinnamaldehyde
The majority of the study participants (21 of 24) reported 
moderate intensity of itch rated on an ordinary VAS scale 
(0–10) following the application of trans-cinnamaldehy-
de (non-responders: n = 3). No subjects reported itch fol-
lowing vehicle application. The mean peak itch intensity 
was 5.18 ± 0.32 (VAS 0–10) and occurred 7 min after the 
application of trans-cinnamaldehyde, while the average 
itch intensity was 3.26 ± 0.46 (Fig. 1a). The subjects were 
instructed to report any sensation occurring along with 
itch (e.g. warmth, burning, or stinging sensation) during 
trans-cinnamaldehyde exposure. Eight volunteers repor-
ted an innocuous warm or non-painful burning sensation 
together with itch and 3 described a painful burning 
sensation. The rest of the volunteers (n = 13) only repor-
ted a pure sensation of itch. The trans-cinnamaldehyde-
evoked itch area drawn on the arm-charts did not show 
any significant differences (p = 0.122) between females 
(20.71 ± 2.35 cm2) and males (16.54 ± 1.23 cm2) and no 
notable pattern in terms of proximal-to-distal or medial-
to-lateral dispersion. An insignificant trend towards better 
abilities to accurately localize itch on dominant arms was 
noted. The detailed temporal itch profile for prolonged 
trans-cinnamaldehyde exposure conducted in a subgroup 
of 4 healthy volunteers showed itch latency and peak 
features resembling those of the main study cohort, and 
in prolonged exposure the sensation of itch had subsided 
completely in all 4 subjects at 33 min after a slow decline 
from 2 (VAS 0–10) at 14 min. 
Flare, skin blood flow and temperature
The application of trans-cinnamaldehyde evoked a 
clear vasomotor response reflected on a distinct flare 
area of 18.06 ± 4.59 cm2 and significantly enhanced 
the superficial skin blood flow (Fig. 2a and c) com-
pared with both vehicle and baseline measurements 
(p < 0.001), while no redness was visible following the 
vehicle. No sex-related differences were observed in 
relation to neurogenic flare areas following the applica-
tion of trans-cinnamaldehyde (p = 0.665). The vehicle 
did not affect skin blood flow (p = 0.215). 
Skin temperature also showed an increase after appli-
cation of trans-cinnamaldehyde compared with vehicle 
(p < 0.0001). Vehicle did not affect skin temperature 
(p = 0.317) (Fig. 2b). Based on thermography images 
males generally had a higher 
mean baseline skin temperature 
than females (p < 0.001). Howe-
ver, no sex differences were found 
in response to the application of 
trans-cinnamaldehyde when as-
sessing absolute values. When 
normalization to the baseline 
skin temperature was performed 
and the relative change in skin 
temperature was assessed bet-
ween the sexes, females exhibi-
ted significantly larger increases 
in skin temperature than males 
(p = 0.0336), indicating that the 
lower baseline temperatures are 
compensable during neurogenic 
inflammation. No significant dif-
ferences were found in superficial 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2103
Fig. 1. (a) Temporal profile of 10 min trans-cinnamaldehyde exposure (n = 21). Black arrows denote the 
start of administration and the removal of the cinnamaldehyde patch at 10 min. (b) Areas of alloknesis 
(von Frey and brush) and hyperknesis (pinprick) in cm2 following administration of trans-cinnamaldehyde 
and vehicle (n = 21). (**p < 0.01, ***p < 0.001). Vehicle evoked no response to the brush strokes. 
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blood flow and skin temperature between the means of 
the 3 × 3 cm region of interest area (ROI) and the 5 × 5 
cm ROI area in response to trans-cinnamaldehyde, in-
dicating a significant axon-reflex flare extending from 
the application area. 
Sensitivity to mechanical stimulation
The mean mechanical pain threshold (MDT) at baseline 
was 27.3 ± 2.3, while the mean MDT was 5.3 ± 0.13. 
Following the application of trans-cinnamaldehyde, 
but not the vehicle, significant areas of both hyperk-
nesis and alloknesis developed. The results are shown 
in Fig. 1b. No sex differences were detected in any of 
the mechanical response parameters. Following trans-
cinnamaldehyde and vehicle application, the area of 
hyperknesis was mapped. The area of hyperknesis 
was detected in the trans-cinnamaldehyde-treated arm 
(p = 0.001 compared with the vehicle). 
All participants developed a small area 
of alloknesis to von Frey following the 
application of trans-cinnamaldehyde 
(p = 0.002 compared with the vehicle). 
Participants developed an area of se-
condary dynamic alloknesis in response 
to stimulation by light brush following 
the application of trans-cinnamaldehyde 
(p = 0.017 compared with vehicle).
Correlations
Positive correlations were found bet-
ween blood flow and skin temperature 
(p = 0.0256), itch area and blood flow 
(p = 0.0264), and itch area and skin tempe-
rature (p = 0.004). No other significant po-
sitive or negative correlations were found 
between any other measured parameters, 
including, for example, between mecha-
nical detection threshold and alloknesis. 
DISCUSSION 
This study represents the first systematic 
investigation of the topical application of 
5% trans-cinnamaldehyde as an inducer 
of itch and itch-related dysesthesias in 
humans. We propose that trans-cinna-
maldehyde could be useful as a human 
experimental surrogate model of itch. A 
distinct flare area, together with areas of 
alloknesis and hyperknesis, were detected 
in addition to a moderate evoked itch. The 
model generally showed no sex difference 
in response to the trans-cinnamaldehyde. 
This model might be applicable for stu-
dying TRPA1-facilitated itch in humans 
and can also be utilized in the testing of known or novel 
anti-pruritic drugs; however, it needs further investiga-
tion for validity and reproducibility and it is not exempt 
from limitations, including potential single observer bias, 
a relatively small sample size and limited dose-response 
data. Moreover, a few subjects (n = 3/24) did not report 
any sensation of itch in response to trans-cinnamalde-
hyde. The cause of this specific non-responsiveness is 
unknown, but TRPA1 is known to be subject to genetic 
variability, e.g. variant rs11988795 G.A, with resultant 
phenotypical differences that affect pain thresholds (32). 
Trans-cinnamaldehyde-induced itch
Findings have highlighted a complex processing of itch 
signalling from periphery to the central nervous system 
with a high diversity in mediators and receptors invol-
Fig. 2. (a) Skin blood flow (a.u) in a 5 × 5 cm region of interest (ROI) area surrounding the 
application area. Trans-cinnamaldehyde enhanced the skin blood flow compared with vehicle 
(***p < 0.001). Typical laser speckle contrast images are shown below. (b) Skin temperature 
(°C) in the same application areas. Trans-cinnamaldehyde enhanced the skin temperature 
compared with vehicle (****p < 0.0001). Typical thermographic pictures are illustrated below. 
(c) Longitudinal dispersion of neurogenic inflammation. Cinnamaldehyde caused a significant 
spatial spreading of neurogenic inflammation beyond the 3 × 3 cm application area, while 
the vehicle did not alter superficial blood perfusion. Grey represents the area of application. 
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ved (1). Several members of the TRP channels family, 
including TRPV1, TRPV3 and TRPA1, contribute both 
to pain and itch signalling in sensory neurones (14, 15, 
17, 33, 34). TRP channels are not only expressed on 
sensory neurones, but also on cutaneous non-neuronal 
cells (e.g. keratinocytes) (20, 35), which makes it pos-
sible for an itch cross-talk between skin cells and sensory 
neurones. Basic and pre-clinical studies have revealed 
that histamine-dependent itch is mediated via TRPV1+ 
mechano-insensitive C-fibres (33), while histamine-
independent itch is probably conveyed via TRPA1+ po-
lymodal C-fibres (16, 17). Both of these channels have 
dual role (e.g. pain and itch transductions) and can be 
activated by endogenous and exogenous stimuli. In ad-
dition, cross-reaction (e.g. desensitization) is not uncom-
mon between TRP channels (36). TRPA1 is also required 
as a downstream mediator for itch signalling by agonists 
such as chloroquine, bovine adrenal medulla 8-22 peptide 
(BAM8-22) and hydrogen peroxide (16, 17). 
Trans-cinnamaldehyde is one of several exogenous 
TRPA1 agonists and it has been applied to human skin 
(e.g. forearm) and oral mucosa in different concentra-
tions, ranging from 0.1% to 10% (37, 38). In the current 
study a median concentration of 5% was applied and a 
moderate level of perceived itch was found in the study 
population (mean peak itch intensity: 5.18 on VAS0–10). 
Some subjects (n = 8/24) also reported a warm or non-
painful burning sensation accompanying the itch. In 
line with our observations, Namer et al. (21), who also 
applied cinnamaldehyde on the volar forearm of healthy 
volunteers, but at a higher concentration (10%), repor-
ted burning pain in all subjects, but accompanying itch 
sensation in only 6 out of 10 subjects (60%). Based on 
this observation and other previous reports (24), it is 
possible that the effect of cinnamaldehyde is concen-
tration-dependent and the ratio between the sensation 
of itch and burning pain might be based on the applied 
concentration. It is established that punctate delivery 
of capsaicin causes itch comparable with histamine or 
cowhage spicules, while injected capsaicin primarily 
elicits burning pain (39, 40). Similarly, Keele & Arm-
strong (41) showed, as early as 1964, that application of 
histamine at higher concentrations causes pain, but not 
itch. Differentiation or transition of perceived sensation 
as itch or pain, is likely a consequence of the degree 
to which additional nociceptive C-fibres are activated 
and could also explain why higher concentrations of 
cinnamaldehyde primarily cause burning pain, while 
lower concentrations mostly cause itch. 
Burning sensation following cinnamaldehyde, con-
comitant with itch or alone has also been linked to the 
co-expression of TRPA1 on a subpopulation of TRPV1-
positive neurones (15, 21). It is known that TRPV1 is not 
activated by cinnamaldehyde concentrations of up to 2 
mM (24), which supports the notion of a distinction be-
tween burning sensation and itch based on concentration. 
Interestingly, cinnamaldehyde (0.5–5 mM) specifically 
activates the warmth/heat-sensing channel TRPV3 (24), 
which is also one of the targets identified for potential 
treatment of itch (34, 42). Moreover, it has been demon-
strated that cinnamaldehyde inhibits TRPM8 activation, 
a receptor to convey a cooling sensation known to al-
leviate itch (2, 43). Although cinnamaldehyde has been 
found to evoke TRPA1-mediated itch (44), no human 
experimental studies have assessed cinnamaldehyde in 
relation to itch. Further investigation of the pruritic effect 
of trans-cinnamaldehyde in human skin should involve 
determining TRP-involvement, e.g. by pre-treatment 
with specific TRPV1-antagonists, such as SB705498 
or 4-tert-butylcyclohexanol. Moreover, assessment of 
cross-sensitization or de-sensitization of TRP channels 
following the application of cinnamaldehyde alone, or 
in combination with, for example, menthol or capsaicin, 
would help enhance our understanding of the effect of 
cinnamaldehyde and whether it desensitizes epidermal 
nerve fibres in a manner analogous to that of capsaicin, 
and thus has potential therapeutic value. 
Trans-cinnamaldehyde-induced vasomotor responses 
Following application of trans-cinnamaldehyde, a flare 
area was detectable beyond the application site in all 
volunteers, which was absent in the vehicle-treated arm. 
These findings are in line with findings by Namer et al. 
(21), who also showed a cinnamaldehyde-evoked axon-
reflex-flare (21). Flare is probably due to antidromic 
activation of the far branches of CMi-fibres that leads to 
release of vasoactive substances, such as calcitonin-gene 
related peptide (CGRP), within the peripheral tissues (45, 
46). There is also a possibility of activation of mast cells 
and other non-neuronal cells, e.g. keratinocytes (20), that 
also express TRPA1 and respond to cinnamaldehyde. 
However, this is unlikely to be the main mechanism 
behind the observed flare, since release of histamine is 
usually accompanied by a wheal reaction (47), which 
was not observed in the present study. Significant flare 
is an uncommon finding in non-histaminergic models 
of itch, but a normal finding in histamine-dependent 
itch, typically characterized by both wheal and flare 
reactions. A warranted elucidation of the mechanistic 
basis of this model should test whether the induced itch 
and vasomotor reaction responses are neurogenically 
maintained (i.e. by lidocaine use) and/or partly refractory 
to antihistamines; hence, elucidating whether the model 
partially relies on activation of histaminergic C-fibres. 
Trans-cinnamaldehyde-induced alloknesis and hyperknesis
This study is the first to show the development of areas 
of alloknesis and hyperknesis on human skin follo-
wing application of trans-cinnamaldehyde. Areas of 
alloknesis and hyperknesis to mechanical stimuli have 
previously been detected in both histamine-dependent 
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and histamine-independent models (such as cowhage 
and punctate capsaicin), typically found to be signi-
ficantly larger than the modest areas reported herein 
(28, 39, 48). The phenomenon has also been reported 
in animals, where light touch evoked scratching beha-
viour (49). In addition, alloknesis is frequently seen in 
patients with chronic itch (50). Mechanistically, deve-
lopment of alloknesis and hyperknesis probably relies 
on both peripheral and central sensitization. Peripheral 
sensitization results from increased excitability of the 
primary itch-sensing afferents (9). This theory, although 
not yet confirmed in humans, has been investigated in 
animal models, where direct evidence was found that, 
in the dry-skin mice model, neurones in the dorsal root 
ganglion responded markedly higher to SLIGRL-NH2 
(a protease-activated receptor (PAR)-2 agonist) and 
serotonin (5-HT), but not to histamine (51). In terms of 
central adaptation, a prolonged or intense itch stimulus is 
proposed to cause increased responsiveness of the spinal 
neurones conveying itch to the brain, whereby activation 
of low-threshold mechanoreceptors and primary itch-
receptive afferents can generate spinal signals of itch and 
increased sensation of itch (respectively) (49). However, 
it is unlikely that spinal mechanisms are dominant in 
the modest alloknesis and hyperknesis observed in the 
present study, since the areas generally do not extend 
beyond the area of application, a feature that normally 
signifies involvement of the central components.
Sex-related differences 
Although significant sex differences are well docu-
mented in relation to pain processing, very limited data 
is available on acute and chronic itch (26, 52). In the 
present study, none of the cinnamaldehyde-evoked re-
sponses, except the relative change in skin temperature, 
were sex-dependent. This was related to the detection 
of higher skin temperatures in males compared with 
females at baseline, which is probably a consequence of 
males tending to have a higher basal metabolic rate and 
less subcutaneous fat (53). An insignificant tendency 
towards higher skin blood flow responsiveness among 
females was observed. Whether these observations 
would show up as a significant sex-related response 
should be assessed in a larger study population, in which 
parameters such as age, ethnicity and skin pigmenta-
tion could also be accounted for. Although being very 
limited evidence, it was noted that 2/12 males reported 
a burning sensation, whereas 6/12 female participants 
reported a burning sensation. This is in line with a study 
by Hartman et al. (26), wherein it was elucidated that 
females accentuated the burning component induced 
by pruritic stimulation (by punctate histamine) more 
frequently than their male counterparts. Moreover, 
the results are in line with the general consensus that 
females are more sensitive to pain stimulus and thus it 
is likely that a potential painful component of any itch 
model will manifest more in females (54, 55). 
In summary, topical application of 5% trans-cinna-
maldehyde proved feasible as a surrogate human model 
of itch, also encompassing itch-related dysesthetic 
states of alloknesis and hyperknesis, albeit to a lesser 
extent than is observed following the application of 
histamine or cowhage spicules. Trans-cinnamaldehyde 
was well-tolerated and showed no sex-dependency in 
relation to itch intensity, area of alloknesis, and hyperk-
nesis. This model can assist in further understanding of 
the contribution of TRP channels to itch and pain at a 
human level, or serve as a suitable model to screen no-
vel human anti-pruritic agents directed at, for example, 
TRPA1 or upstream target candidates. 
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